Lineage Cell Therapeutics (LCTX) Gains from Sales and Divestitures (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Gains from Sales and Divestitures of $67000.0 for Q1 2026, little changed on a YoY basis from $67000.0 in Q1 2025, and down 22.09% quarter-over-quarter from $86000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Gains from Sales and Divestitures (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Gains from Sales and Divestitures for 16 years, with the latest figure at $67000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures changed 0.0% year-over-year to $67000.0; the trailing twelve-month figure through Mar 2026 stood at $67000.0 (changed 0.0% YoY), and the FY2025 full-year result was $86000.0, up 28.36% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $67000.0, down from $86000.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $86000.0 in Q4 2025, with the low at $16000.0 in Q1 2022.
- Historically, Gains from Sales and Divestitures has averaged $61823.5 across 5 years, with a median of $67000.0 in 2024.
- Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures sank 50.0% — and 2023, when it soared 400.0%.
- Lineage Cell Therapeutics' Gains from Sales and Divestitures stood at $31000.0 in 2022, then soared by 158.06% to $80000.0 in 2023, then declined by 16.25% to $67000.0 in 2024, then advanced by 28.36% to $86000.0 in 2025, then declined by 22.09% to $67000.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $67000.0 (Q1 2026), $86000.0 (Q4 2025), and $67000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67,000.00 |
| Mar 31, 2026 | 67,000.00 |
| Dec 31, 2025 | 86,000.00 |
| Dec 31, 2025 | 86,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Sep 30, 2024 | 67,000.00 |
| Sep 30, 2024 | 67,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Dec 31, 2023 | 80,000.00 |